


Презентация 1

AstraZeneca



**Ускорение развития
партнерства между
Китаем и глобальной
инновационной экосистемой
в здравоохранении**

2024.09



Необходимо продолжать реализовывать инновационную платформу Китая для создания реальных партнерств в России

Визит делегации из Китая в сфере инноваций:
28 ноября - 1 декабря, 2023



Программа привлечения ключевых партнеров

1. Национальный конгресс по вопросам здравоохранения, организованный МЗ: Круглый стол «Россия и Китай: инновации в медицине и организации здравоохранения»
2. Круглый стол в РСПП
3. Заседание в Деловой России
4. Встреча партнеров по инновациям: госпитали, торговля, технологии и фонды

Достижения по локализации китайских инноваций

Мониторинг при сахарном диабете



Онкологическая лаборатория



Точная диагностика онкологических заболеваний



ИИ для диагностики



AstraZeneca как стратегический партнер, формирует инновационную экосистему Китая в интересах местной системы здравоохранения

Клеточная и
генная
терапия



Радио-
фармпрепараты



Интегрированное
медизделие и
препарат



Система
нанодоставки
препарата



Ранняя
диагностика



Умные
медизделия



Цифровое
здравоохранение
и ИИ




CRO и
лабораторные
исследования



В AZ Китай сформирована комплексная платформа глобализации инноваций

Модель
совместных
инноваций



CCiC

Китайский центр
коммерциализации инноваций

Создание интегрированных
решений по лечению заболеваний
на основе полного курса лечения

17 инновационных решений
Реализовано в + 1500
госпиталей

Экосистема
инкубации
инноваций



iCampus

Международный кампус наук о
жизни

Единая инкубационная платформа
для предприятий в сотрудничестве с
правительственными ведомствами

+ 170 резидентов
**+ 300 экосистемных
партнеров**

Ускорение
прогресса
инноваций



Фонд AZ-CICC

AZ-CICC фонд
индустрий здравоохранения


Инкубация инноваций в сфере
здравоохранения с помощью
капитальных ресурсов

**+ 20 инвестиционных
портфелей**
+ 10 международных сделок



Быть лучшим партнером государства по развитию экосистемы

Партнерство с государством для установления взаимосвязи с основными заинтересованными сторонами



Разработка
НПА

Реестры

Помещения и
инфраструктура

Инвестиционный
капитал

Привлечение
ресурсов

... ..

Фокус на заболеваниях и возможности индустрии



Уси

- Сахарный диабет, ССЗ, ХБП
- Рак Легких



Шанхай

- НСС
- Лаборатория ИИ
- Экосистема НИОКР



Пекин

- Рак молочной железы



Ханчжоу

- Цифровое здравоохранение



Чэнду

- Традиционная китайская медицина



Циндао

- Респираторные болезни
- Орфанные заболевания



Гуанчжоу

- Точная диагностика онкологических заболеваний



Гонконг

- Продвинутая терапия



Уси iCampus - кластер инновационной экосистемы созданный за 4 последних года



Яркие примеры комплексного экосистемного партнерства



Инвестиции или приобретения китайских ведущих инновационных компаний для развития бизнеса в мире

Национальный комитет по цифровым инновациям в здравоохранении



Партнерство с национальным ИИ институтом для создания системы Rep-AI для пациентов с раком молочной железы



CGM инвестиции, инкубатор и партнерство (на уровне Китая и мира)



NECP (Платформа для вовлечения клиентов следующего поколения)



Центр метаболических нарушений и научный парк



Платформы международного сотрудничества с инновационной экосистемой Китая

Бразилия Fiocruz



AZ Китай Экосистемная конференция




Вьетнам Министерство инвестиций



ВОАО Форум для Азии: Инновации без границ



Саудовская Аравия MNGHA/KAIMRC



Совместный инновационный хаб - пример научного сотрудничества Саудовской Аравии и Китая

Сотрудничество компании AstraZeneca с министерством здравоохранения Саудовской Аравии

“ Our National Biotechnology Strategy works to address challenges and seize opportunities in a rapidly growing sector, serving as a roadmap for becoming a global leader in biotechnology by 2040. The strategy focuses on enhancing the health and well-being of our citizens, stimulating economic growth, creating skilled job opportunities, and attracting investments to foster new industries, all while promoting a sustainable environment and contributing to Vision 2030. ”



His Royal Highness Prince
**Mohammed bin Salman
bin Abdulaziz Al Saud**

Crown Prince, Prime Minister, and Chairman of the Council of Economic and Development Affairs

The National Biotechnology Strategy 01



Leon Wang
Executive Vice President, International and
China President, AstraZeneca



KAIMRC



Dr. Abdelali Haoudi



Dr. Ahmed Almazroa



Dr. Mai Alajaji

AstraZeneca



Faisal Mahrous



Hicham Mirghani



Chandler Chen



Ghaleb Al Ahdab



Yolanda Han



Shuangshuang Yu



Ruijie Zhang



Saad Almatrafi

Устойчивая инновационная платформа, которая направляет национальную стратегию здравоохранения в соответствии с двусторонним вектором сотрудничества

Интегрированное вовлечение органов власти и учреждений Саудовской Аравии

Партнер государства в области здравоохранения




Партнер регулятора



Партнер по инвестициям



Партнер по науке



Комплексное участие китайских биотехнологических компаний и инновационных партнеров

Партнер по инновациям



Отраслевой партнер



Партнер по науке



Аналитический и идейный партнер



Китай и глобальный план экосистемы инноваций для страны-партнера

Видение

Получить доступ к китайским инновациям и принести пользу пациентам и системе здравоохранения во всем мире

Миссия

Создание единой платформы для Китая и международных партнеров по инновациям

Построение модели двустороннего партнерства

2030 Стремление:

Партнер выбора и единая платформа для масштабирования инноваций в мире.

Возможность быстрой реализации:

Сформировать страна-страна платформу для сотрудничества

Выбор и локализация китайских инноваций

2030 Стремление:

Масштабировать +100 инноваций (партнер/модель/решение) в мире

Возможность быстрой реализации:

Формирование для страны-партнера локальных партнерств

Наращивание возможностей системы

2030 Стремление :

Разработать комплексную программу обмена в сообществе медицины, образования, науки

Возможность быстрой реализации:

Формализовать программу обмена на базе проектов

Совместно создать узнаваемую платформу экосистемы

2030 Стремление:

Быть признанной как лидирующая глобальная платформа для партнерства в инновациях

Возможность быстрой реализации:

Организация ежегодных мероприятий на базе экосистемы



Ускорять партнерство Китая и глобальных экосистем в инновациях в здравоохранении

С нетерпением
ждем
нашего
партнерство



Презентация 2

Airdoc





More Intelligence, Better Care

07/2024



Airdoc

Global market leader and pioneer in the field of AI-based retinal imaging*

Founded in 2015, Airdoc strives to provide comprehensive and multi-faceted AI solutions that utilize retinal imaging for the early detection, auxiliary diagnosis, and health risk assessment of chronic diseases, as well as the prevention and control of myopia.

*Source: Frost & Sullivan



2015

- Airdoc founded
- Completed Pre-A round funding




2019

- Awarded Wu Wenjun Artificial Intelligence Science and Technology Progress Award, which is the highest AI award in China



2021

- Listed on the main board of Hong Kong Stock Exchange as the first Medical AI Share



2024

- China's First Private Deployment of a Medical Consortium
- Airdoc's "Wanyu" Large Model Algorithm Passes National Deep Synthesis Service Evaluation



- Presented at Microsoft Build 2017, the biggest event for global technology developers

2017



- Obtained the National Medical Products Administration Class III medical device as the first of its kind
- Obtained CE certificate from the EU

2020



- Birth of the "Integrated Diagnosis and Treatment" AI Home Treatment System
- Obtained FDA Certification

2023



Products and Services

Unmet Needs for Early Detection and Management of Many Chronic Diseases



43.3%¹

awareness rate

129.8 million

adult patients with diabetes in China




51.6%²

awareness rate

245 million

adult patients with hypertension in China



43%²

awareness rate
(chest pain and discomfort related to the heart)

No. 1

cause of death in China is cardiovascular disease



3.08%³

awareness rate

At least 1


in 5 people die from a stroke

[1] Weiping Teng, BMJ. 2020; 369: m997.

[2] National Center for Cardiovascular Diseases. Annual Report on Cardiovascular Health and Diseases in China 2019 [M]. Beijing: China Science Publishing & Media, 2020.

[3] Yilong Wang, Xingquan Zhao, Yong Jiang, et al. Prevalence, knowledge, and treatment of transient ischemic attacks in China. Neurology, 2015;84:1-8.

[4] TIA is commonly referred to as a "mini-stroke," which can indicate a high likelihood of a stroke in the near future and requires immediate medical attention.



Uncover chronic diseases with one fundus photograph

Endocrine disorders



Cardiovascular diseases



Nervous system disorders



Eye diseases



- Retinal image captured using non-mydratric fundus camera.
- The image is used to check the condition of blood vessels and nerves.

- **The retina is the only direct way to observe the body's blood vessels and nerves. A retinal image offers direct medical evidence for assessing the progress of multiple diseases.^[1]**
- **Regular monitoring for dynamic changes in retinal images allows for the early diagnosis and treatment of diseases and reduces medical costs.**

[1] Many influential medical guidelines and papers have expressed that retinopathy is an important indicator of various types of diseases, such as the following:

- Chinese Diabetes Society. Guidelines for the Prevention and Treatment of Type II Diabetes Mellitus in China (2020 Edition [J]). Chinese Journal of Diabetes Mellitus, 2021,13(4): 315-409.
- Hypertension Association (China). China International Exchange and Promotive Association for Medical and Health Care Hypertension Branch, Revision Committee of Chinese Guidelines for Prevention and Treatment of Hypertension, etc. Chinese Guidelines for Prevention and Treatment of Hypertension (2018 Edition) [J], Chinese Journal of Cardiovascular Medicine, 2019(1):24-56.
- McGeechan K, Liew G, Macaskill P, Irwig L, Klein R, Klein BE, Wang JJ, Mitchell P, Vingerling JR, DeJong PT, Wittenman JC, Breteler MM, Shaw J, Zimmet P, Wong TY. Meta-analysis: retinal vessel caliber and risk for coronary heart disease. Ann Intern Med. 2009 Sep 15;151(6):404-13.
- Wong TY, Klein R, Couper DJ, et al. Retinal microvascular abnormalities and incident stroke: the Atherosclerosis Risk in Communities Study. Lancet. 2001 Oct 6;358(9288):1134-40.
- Murueta-Goyena A, Del Pino R, Galdós M, Arana B, Acera M, Carmona-Abellán M, Fernández-Valle T, Tijero B, Lucas-Jiménez O, Ojeda N, Ibarretxe-Bilbao N, Peña J, Cortes J, Ayala U, Barrenechea M, Gómez-Esteban JC, Gabilondo I. Retinal Thickness Predicts the Risk of Cognitive Decline in Parkinson Disease. Ann Neurol. 2021 Jan;89(1):165-176.
- Schrijvers EM, Buitendijk GH, Ikram MK, Koudstaal PJ, Hofman A, Vingerling JR, et al. Retinopathy and risk of dementia the Rotterdam Study. Neurology 2012;79:365-70.

A Fundus Camera Specially Designed for Screening the Body Using the Retinas



Fully automatic

Locates the pupils automatically
Focuses on the retinas automatically
Takes pictures automatically
Only **30** seconds required for taking pictures

Fully self-service

No personnel required for operation
Voice prompts
Instant report

First approved

The portable fundus camera is
the first to be approved in China
for sale by the NMPA
(AI-FD16)

Portable

Only **2.2kg**
Plug-and-Play
Support powered by a **portable battery**



AI-FD16aF



5

continents

50

countries or regions

13+

Overseas
Registration
Certificates

6.83

million+

Number of Test
Cases

Nearly 30

million+

Total Number of
Users Served

As of the end of December 2023, Airdoc's services have reached over 50 countries and regions across five continents, serving nearly 30 million users in total.*

* 截至2023年12月底数据


Research Achievements

Scientific research achievements have been published in international authoritative academic journals




Since 2018, published high-level papers **50+**, Cumulative impact factor **400+**

Facilitate the innovative application of artificial intelligence technology in medical research and clinical practice




《The Lancet · Digital Health》
(IF: 36.615)




《Science Bulletin》
(IF: 20.577)



《Age and Ageing》
(IF: 12.782)




《Cell Reports Medicine》
(IF: 16.988)



《JAMA Network Open》
(IF: 13.4)

Research Achievements

Published an article in The Lancet



- ★ **Cover recommendation** The Lancet Digital Health
- ★ To date, this article offered the **largest scale** real-world research in the world on detecting multiple diseases via AI-based retinal imaging
- ★ IF: **36.615**
- ★ At the same time, Amitha Domalpally, research director at Fundus Photograph Reading Center, University of Wisconsin-Madison (a leader in ophthalmic imaging evaluation) released a review, saying the research was “**a step in the right direction.**” for medical artificial intelligence research
- ★ **The Zhongshan Eye Center led 16 medical and research institutions to verify data**
- ★ Used **260,000** retinal images that covered 28 provinces/cities throughout China and 51 medical institutions
- ★ The research proved that the system had an average **AUC=0.968, for an accuracy comparable to an ophthalmologist***


*DI, A , et al. "Application of Comprehensive Artificial intelligence Retinal Expert (CARE) system: a national real-world evidence study." The Lancet. Digital Health 3.8:e486-e495.

Research Achievements

Science Bulletin released an important article



- ★ It was the **first study** in China to attempt to combine AI technology and information from fundus photographs to predict the risk of cardiovascular disease
- ★ With **400,000** retinal images, an AI algorithmic model was developed based on fundus photographs. The study then estimated the risk of ischemic cardiovascular disease (ICVD) in the next ten years
- ★ 2022 IF: **20.577**
- ★ **Peking University Clinical Research Institute and Beijing Tongren Hospital**
Validation results: When screening individuals from borderline/moderate or higher ($\geq 5\%$ / $\geq 7.5\%$) ICVD risk groups, the AUC was 0.971 and 0.976 respectively.*
- ★ For **early detection** in groups with a high risk of ischemic cardiovascular disease, the system played an active role in recommending intervention, monitoring, the assessment of intervention effectiveness, etc.



Traditional assessment method:

- Gather numerous indicators
- Required invasive collection
- Length blood tests (2-4 hours)
- Complex calculations



New assessment method:

- Only requires fundus camera
- Non-invasive collection
- Examination takes 1 minute
- Provides reports immediately



More Intelligence, Better Care



欢迎微信联系我们

Презентация 3

Атоу

AmoyDx

Amoy Diagnostics

an IVD company

breaking barriers

in Precision oncology



www.amoydiagnostics.com

Customer Facing



Leader in Precision Oncology In China

In 2023, reaching **750,000** Chinese patients accepted molecular diagnostics using AmoyDx's assay.



GLOBAL COVERAGE



>75 COUNTRIES

> 500 Hospitals In Europe & Japan

> 600 Hospitals in China

GLOBAL GROWTH (2023-2024)



23.91%

growth YOY

DRIVEN BY INNOVATION



19.47%

Of total revenue
for R&D expenses

59

Patents

PHARMA

> 20 Pharma
Partnerships

> 35 CDx Projects



40 CE-IVDD Registered
Products

27 Class III Medical Device
Registration Certificates

Презентация 4

Dipath




Company Profile

DiPath (HangZhou DiPath Technology Co., Ltd)

China's leading provider of digital and intelligent pathology solutions for hospitals, independent clinical laboratories, research institutions, pharmaceutical companies, etc.

Provide all-in-one service platform, including pathology artificial intelligence, product design and development, clinical trials, research, data analysis, medical device registration and certification.

DiPath has obtained 20 software copyrights, 80+ patents, and 11 Class II medical device registration certificates.



■ Hangzhou ■ Shanghai ■ Wuhan ■ Xi'an

20 years Deep cultivation on AI pathology


7 years Leading digital pathology market

200 million Cumulative Financing

Near 1000 Hospital partners

50%+ Employees graduated from top Univ.

30%+ Employees with a Ph.D. degree





■ CICC ■ LEGEND ■ JH Capital
■ SZ Capital ■ IDG ■ JM Capital

CDx and ADC, personalized diagnostics, and AI in routine clinical usage



中国国际进口博览会
CHINA INTERNATIONAL
IMPORT EXPO

Recognition from
Fortune Global 500
Companies



3rd CIIE: PD-L1 Lung Cancer Module with AstraZeneca

4th CIIE: CD30 Lymphoma Module with Takeda Pharmaceutical

5th CIIE: HER-2 Breast Cancer Module Diagnostic with AstraZeneca

5th CIIE: Cervical Cytology Module with ZEISS AI-Assisted Diagnosis


6th CIIE: Digital Pathology Ecosystem with Roche Diagnostics

6th CIIE: Strategic Cooperation with AstraZeneca in Tumor Digital Pathology




Tumor pathology diagnosis through digital pathology and AI


NSCLC PD-L1 AI Module



Breast Cancer HER-2 AI Module



"Diagnosis-Scanning Integration" Solutions



Seeing beyond
ZEISS Cervical Cell Assisted
Diagnosis System




武田中国

Digital pathology R&D of innovative drugs for positive lymphoma CD30



Positive lymphoma CD30 AI Module



DiPath product lines

DiPath has in-depth understanding of the whole process of microscopic image analysis, independently developed 8 product lines of intelligent diagnosis series, and combined with digital cloud platform services, provide a complete set of solutions for a new generation of AI enabled microscopic image analysis.

D-CleverEye



Define the next generation of intelligent microscope

More intelligent and more accurate diagnosis


D-PathAI



Artificial intelligence diagnosis platform based on microscopic image

20 years of dedicated research; Let AI to upgrade diagnosis experience

D-PathAI Cytology



New cytology artificial intelligence-assisted diagnosis platform

Intelligent digital workflow, insight into every cell


D-PathConnect



Smart remote consultation platform

Simultaneously supports traditional whole-field image consultation and innovative microscopic inquiry methods

Translational Research Driven D-PathDPD



- End-to-end infrastructure and information management system
- Remote consultation, teaching, and residency training system
- Digital slide storage platform

More than 40 modules including tissue, cyto, IHC and molecular

Histopathology

Basic processing

Cytopathology

Molecular pathology

I HE




Immunohistochemistry




01

Gastric Cancer



GC Intelligent Analysis Module





Algorithm Design Route

02


Breast Cancer

KI67/ER/PR/HER-2 IHC & FISH Application




03

Prostate Cancer



PC Intelligent Analysis Module




Algorithm Design Route

04

Other Cancers



Cervical Cytology



Nasal Polyp

Презентация 5

DC Pharma

DC Pharma Introduction

Aug 2024



Corporate Profile

Yantai Dongcheng Pharmaceutical Group Co., Ltd. ("DC Pharma") was established in 1998 and listed on the Shenzhen Stock Exchange in May 2012. (stock code 002675)

After more than 20 years of development, **DC Pharma** has now become a large pharmaceutical enterprise group covering four major fields, including **APIs, Drug Products, Nuclear Medicine & Radio-pharmaceuticals** and Health Products, integrating drug research and development, production, and sales.

24

Years of
History

4

Key
Business
Units

40+

Countries

80+

Subsidiaries

2000+

Staffs






APIs

Global ranking #1
Chondroitin business is consistently ranked no1.

Global ranking #3
China ranking #1
For Heparin API in 2022



Drug Products

Rich variety, recognized brand name
Covering multiple therapeutic areas, with a wide range of 49 different drug products.



Radio-Pharmaceuticals

China ranking #2
Market leader in radio-pharmaceutical production and distribution network, from conventional nuclear medicine, PET drugs to therapeutics.



Health product

Rapid growth
Started in 2021, health product is launched to market as supplements to preventive healthcare

API business

With vertically integration of industrial chain, DC pharma established global expansion of the heparin and chondroitin API market worldwide.



Global ranking #1
Chondroitin business is
consistently ranked no1.

Global ranking #3
China ranking #1
For Heparin API in 2022


Radio-pharmacy (^{99m}Tc , ^{131}I , ^{125}I , ^{18}F , etc)

Nationwide distribution of short half-life drugs

Centralized Supply of long half-life drugs



- ★ 投产核药中心 28个
manufacture site in operation 28
- 在建核药中心 11个
manufacture site under construction 11



图例

- 国界
- 省、自治区、直辖市界
- 特别行政区界
- ★ 北京 首都
- 天津 省级行政中心
- 保定 地级行政中心
- 和田 县级行政中心

1 : 16 000 000

审图号: GS(2016)2923号
自然资源部 监制



CDMO

- ◆ Radiochemistry Services
- ◆ Production of Radiopharmaceuticals

Pre-Clinical Studies

- ◆ In vitro radioligand receptor/immuno-binding assays
- ◆ Pharmacokinetics and Bio-distribution
- ◆ Receptor Occupancy
- ◆ In vivo efficacy of Radiopharmaceuticals
- ◆ Toxicity of Radiopharmaceuticals

Clinical Studies

- ◆ Clinical imaging trials of novel drugs
- ◆ Clinical trials of novel radiopharmaceuticals
 - IIT/Phase 0 Studies
 - Phase I - Single-site Studies
 - Phase II/III - Multi-site Studies

Thank you!

Презентация 6

Gan & Lee

Gan & Lee Pharmaceutical

S



stock code: 603087. SH





Research

1st insulin Glargine, Lispro, and Aspart analog in China

1st self-developed reusable insulin injector in China

30+ pipeline products for diabetes, including weekly insulin & bi-weekly GLP-1

11+ polypeptide, PROTAC, and gene therapy Platforms

Development

1100+ Subjects included in phase III clinical trials across US and EU

5+ New molecules projects under clinical trial, including bi-weekly GLP-1

57 registration certificates for insulin in **21** countries

Production

3 manufacture sites for biologics, devices, and chemical drugs

Capacity fulfill **50%** of global insulin demand

- API: 3,500 KG + 8,000 KG
- Preparation: 200 million+300 million

12 GMP certificates from different countries, including **EU GMP** and **US GMP** in process

Commercialization

China:

No. 1 Insulin market share in local competitors

2,000+ employees in sales team

30,000+ hospitals coverage

Global:

Products launched in **18** countries

41 global partners, including Sandoz

11 technology transfer projects finished, and **6** in process

Market Cap

A-share Market listed company since 2020

Market value surged **73** times in **10** years from 2010

Operating revenue growth rate **52.31%** in 2023 compared with 2022

Contact Us



No.8, Nanfeng West 1st Street, Huoxian, Tongzhou District,
Beijing, 101109, China




+86 (010) 5645 2796



www.ganlee.com




jingjing.zhang@ganlee.com




Презентация 7

Genetron

Genetron Health Corporate Introduction



Company Overview



The name "Genetron" is derived from Darwin's "theory of pangenesis", which proposed the initial definition of human genetic material - genes.

Genetron Health is a leading precision oncology platform company in China. We specialize in the research and application of cancer genomics, providing early screening, medication guidance, prognosis and monitoring, and new cancer drug development services that cover the entire spectrum of cancer management. We are committed to applying innovative genomics technology to cancer-related diagnosis and treatment and to ultimately defeating cancer.

Vision

Healing cancer through relentless exploration and innovation in cancer genomics

Mission

Defeat cancer, protect life



Our Proprietary Technology

One-step Seq Method
Mutation Capsule



Our Global Recognition

CAP, CLIA, ISO 15189

Our Business Partners

Hospital

Research
Institution


Biopharma

Physical
Examination

Government

Insurance
Institution

Comprehensive Solutions for the Full Cycle of Cancer Care




A comprehensive suite of customized, safe, and reliable products and services that caters to the needs of patients at different cancer stages across multiple cancer types, all while considering different financial situations.


Early Cancer Screening

Basic Research

- Cooperated with the Cancer Hospital of the Chinese Academy of Medical Sciences, and developed a high-sensitivity, high-specificity screening method, HCCscreen and its core technology Mutation Capsule. The research results were published in *PNAS*.



- In December 2022, a research paper based on Genetron Health's early cancer screening technology Mutation Capsule Plus was published by Science Translational Medicine.



Product Conversion and Application

- Genetron Health has a full-cycle solution for the management of early cancer screening, including genetic risk assessment of fatty liver and hepatitis test; early liver cancer screening, HCCscreen and HCCscan; and MRD for liver cancer, HCC-MRD.
- HCCscreen: Released new prospective cohort study data on HCCscreen for early liver cancer screening. The primary outcome showed that HCCscreen achieved 88% sensitivity and 93% specificity on 1,615 HBsAg+ patients.
- HCCscan: Already started the enrollment of subjects in the clinical trial of the PCR-based HCCscan with seven participating institutions as of December, 2023.
- HCC-MRD: Tumor-naive MRD designed for liver cancer, can offer lower cost and faster turnaround times, and detect the mutations in new lesions.



Domestic and International Recognition

Participated in a key national R&D project for three cancer types (liver, lung and gastro-intestinal), led by China's Ministry of Science and Technology.

国家重点研发计划“重大慢性非传染性疾病防控研究”重点专项 2019 年度项目立项表

序号	项目编号	项目名称	项目牵头单位
1	2019YFC1315700	恶性肿瘤筛查早诊的液体活检技术研发及评价研究	中国医学科学院肿瘤医院

HCCscreen received the Beijing New Technology and New Product (service) certificate.



Blood-based NGS test for early detection of hepatocellular carcinoma, HCCscreen, granted Breakthrough Device designation by the US FDA.



Diagnosis and Monitoring (LDT)

- Cover solid tumors and hematological tumors: lung cancer, gastric cancer, colorectal cancer, liver cancer, thyroid cancer, breast cancer, esophageal cancer, cervical cancer, brain tumors, pancreatic cancer, and take the leadership in the research and study on brain tumors worldwide
- Support tissue and liquid biopsy testing
- Include specific tumor (Lung Basic etc.) and pan-solid tumors tests (Onco Panscan, Onco Sonar etc.)




Central Nervous System

- Glioma Basic: gene test for glioma (Tissue)
- Brain Focus: gene with well-chosen for brain tumors (Tissue)
- Brain PanScan: pan-brain tumors panel (Tissue)
- Medulloblastoma Molecular Subtyping Gene Testing (Tissue)
- Brain Tumors 68 Genes Testing (CSF)
- Onco Sonar: pan-brain metastases panel (CSF)
- Whole-Exome Sequencing (21,000 Genes) for Brain Tumors (Tissue)



Thyroid Neoplasms

- Full-Cycle Gene Testing for Thyroid Cancer (Tissue)
- Full-Cycle Plus Gene Testing for Thyroid Cancer (Tissue)
- Onco PanScan: pan-solid tumors panel (Tissue/Blood)
- Whole-Exome Sequencing (21,000 Genes) (Tissue)




Bone and Soft Tissue Sarcomas

- Onco PanScan Gene Test for Whole System Sarcoma



Hematologic Neoplasms

- Seq-MRD®: molecular residual disease of hematological tumors (Bone Marrow/Blood)



Lung

- PD-L1 Immunohistochemistry Testing
- Lung Basic: gene testing for lung cancer (Tissue)
- Onco Basic Plus: gene testing for solid tumors (Blood)
- Onco Focus (Lung Cancer): gene with well-chosen for lung cancer (Tissue)
- Onco Sonar: pan-solid tumors panel (Blood)
- Onco PanScan: pan-solid tumors panel (Tissue/Blood)
- GENETRON MRD: molecular residual disease of solid tumors (Blood)
- Whole-Exome Sequencing (21,000 Genes) (Tissue)




Breast

- BRCA 1/2 Testing
- Breast Cancer 21-Gene Assay (Tissue)
- Onco Basic Plus Genetic Testing for Solid Tumors (Blood)
- Onco Focus Genetic Testing for Solid Tumors (Tissue)
- Onco Sonar (Blood)
- Onco PanScan (Tissue/Blood)
- Genetron HRD
- GENETRON MRD
- Whole-Exome Sequencing (21,000 Genes) (Tissue)



Gastrointestinal Tract

- PD-L1 Immunohistochemistry Testing
- Microsatellite Instability (MSI) Testing
- GI Basic: gene testing for gastrointestinal tumors (Tissue)
- Onco Basic Plus: gene testing for solid tumors (Blood)
- Onco Focus (Gastrointestinal Tumors): gene with well-chosen for gastrointestinal tumors testing (Tissue)
- Onco Sonar: pan-solid tumors panel (Blood)
- HRR & Tumor Genetic Susceptibility Gene Testing (139 Genes)
- Onco PanScan: pan-solid tumors panel (Tissue/Blood)
- GENETRON MRD: molecular residual disease of solid tumors (Blood)
- Whole-Exome Sequencing (21,000 Genes) (Tissue)



Urinary System

- PD-L1 Immunohistochemistry Testing
- Onco Urine: gene testing to assess the risk of urothelial tumors (Urine)
- Onco Basic: gene testing for solid tumors (Blood)
- Onco Focus (Prostate Cancer): gene with well-chosen for prostate cancer testing (Tissue)
- Onco Sonar: pan-solid tumors panel (Blood)
- HRR & Tumor Genetic Susceptibility Gene Testing (139 Genes)
- Onco PanScan: pan-solid tumors panel (Tissue/Blood)
- GENETRON MRD: molecular residual disease of solid tumors (Blood)
- Whole-Exome Sequencing (21,000 Genes) (Tissue)

Biopharma Service

精准助力药物研发全周期



Preclinical Discovery Research

Exploration and discovery of candidate biomarkers



Companion Diagnostic Collaboration

Development and registration application of CDx for drug



Central Laboratory Services

Detection of genome relevant to new drug clinical trials



Post-Market Promotion

Real-world studies after drug marketing, joint promotion the commercialization of drugs and CD

Strategic cooperation with 80+ top biopharmaceutical companies and CROs in China and abroad



Professional and Compliance Pharmaceutical Services

First bridging companion diagnostic kit approved by NMPA, after the introduction of the guidance for companion diagnostic kit



Companion Diagnostic Kit of Ayvakit®

- First approved domestic companion diagnostic kit with a full bridging pathway and combining the medicine efficacy data in and outside China
- First domestic companion diagnostic kit entering priority approval process of NMPA, and the drug also received priority approval
- First domestic kit targeting the PDGFRA D842V mutations

First MRD co-developed by a biopharmaceutical company and a precision oncology platform company in China



- The only co-developed NGS-based MRD product for solid tumor in AstraZeneca Global R&D China Center
 - Samples from 30 types of solid tumors have been validated thousands of times against the gold standard, covering lung, colorectal, liver, gastric, cervix, pancreatic, breast, prostate, bladder, rhabdomyosarcoma and etc.
 - Performance superior to industry standards
- | | |
|--------------------------|----------------|
| 80,000X – 100,000X | 0.01% – 95% |
| Average sequencing depth | Detection rate |

For more information, please follow us on our social media




WeChat Official Account



WeChat Channel




Zhihu Official Account



Презентация 8

HIPOWER



HIPOWER

Guangzhou HiPower Pharmaceutical R&D Co., Ltd.



Passion · Efficiency · Dedication · Responsibility

ABOUT US

Established
2009.10.22

Employees
360+



Customers
600+

Projects
1000+

Hospitals in partnership
6000+



Locations in Guangzhou

• Operational Center •

Yuexiu District

Zhu Shi Tong Chuang Huan Dong Plaza

• Medical Center •

Huangpu District


Guangzhou International Bio Island

• Transformation Center •

Haizhu District

Yueke Financial Building

MAIN BUSINESSES



Digital technology empowers the development and transformation of in-hospital formulation



Pharmaceutical company R&D

- Clinical trials for innovative drugs in phases I, II, III, and IV
- Biosimilarity testing for generic drugs
- Clinical trials for medical devices
- Clinical research on stem cells

- Real-world studies
- Cultivation of major categories of traditional Chinese medicine
- Secondary development of traditional Chinese medicine
- Protection of traditional Chinese medicine varieties
- Adverse reaction monitoring
- Comprehensive clinical evaluation

Digital technology empowers real world studies



Sales of Pharmaceutical companies

INTERNATIONAL DISTRIBUTION



CONTACTS:
CEO Shuaishuai Wang
Guangzhou HiPower Pharmaceutical R&D Co., Ltd.
Tel: +86 18903001111
Email: wss@gz-hipower.com



Headquarters location

China (including Hong Kong, Macao and Taiwan)



Asia and the Pacific region

Australia, Canada, Japan, Korea, New Zealand, Indonesia, Philippines, Malaysia, Thailand, Singapore, Vietnam, India, Pakistan, Thailand



EU

Denmark, Sweden, Portugal, Spain, etc.

Презентация 9

Hisky Med



HISKY MED

TusPark
清华科技园

TusPark 清华

COMPANY OVERVIEW

Introduction

Founded in 2010, Wuxi Hisky Medical Technologies Co., Ltd. (HISKY) is a young, dynamic and rapidly growing company, focusing on providing innovative diagnosis and treatment solutions in liver, digestive, respiratory, breast and other diseases, with independent R&D and manufacturing capabilities.



2
R&D
Centers



25%
Employees
in R&D



2500+
Global
Installation



20000
Square meter
Manufacturing Base



Milestones



1993

R&D

Research on Elastography theory and technology in BME of Tsinghua University



2010

HISKY

HISKY founded in July 2010, and launched TE platform.



2012

First Image-Guided TE System

The world's first image-guided non-invasive liver fibrosis diagnostic system, obtained NMPA registration in China in 2012



2014

CE Approval

Certification of TUV SUD Group



2016

Round B Venture Capital

Completed Lenovo Legend Capital and other 16 million USD round B venture capital



2018

US FDA Approval

U.S. FDA 510(k) Clearance



2019

MigTE

Multi-mode fusion probe, integrating ultrasound imaging and elasticity measurement



2020

LivQ-box®

A novel method for non-invasive assessment of liver inflammation

Zaozhuang, Shandong Manufacturing Base

New Factory in Shandong, 20000 Square meters Manufacture Base
Total Investment 30M USD



Beijing R&D



Research on Transient Elastography

TE was proposed by
Professor Ophir in 1991

HISKY launched first TE-based
device in 2010



**Tsinghua University started
research on TE in 1993**


The founding team of HISKY is one of the first teams to
conduct elastography research in the world (since 1993)



- Prof. Bai Jing from Tsinghua University started to conduct research on elastography theory and technology in 1993, which became one of the world's leading research teams in this field.
- Core team of HISKY came from Tsinghua University (Ranked 15th in 2021 QS world university ranking)
- 25% employees are in the R&D team, over 33% of those have Master and PhD degrees.



Hisky – Three Technology Platforms



Intellectual Property Rights

500+ Patent Applications



Invention Patent **135**
Utility Model Patent **57**
Design Patent **26**

China



Invention Patent **269**
Utility Model Patent **4**

International

Patent List


Hisky Global Patents list (Granted)		
Title (Translated, only for reference)	Application no.	Applicant
Data processing method, device, equipment, and storage media	ZA2022/01561	HISKY MEDICAL
Data storage device, method, and readable storage medium	ZA2021/07227	HISKY MEDICAL
Methods and equipment for detecting the viscoelastic parameters of the viscoelastic media	ZA2018/04119	HISKY MEDICAL
Ultrasonic devices and devices that produce mechanical vibration	ZA2018/05986	HISKY MEDICAL
Method and device for the elastic detection of a viscoelastic medium	US15279936	HISKY MEDICAL
Method and device for the elastic detection of a viscoelastic medium	US15280041	HISKY MEDICAL
Method and device for the elastic detection of a viscoelastic medium	US15279994	HISKY MEDICAL
Method and device for the elastic detection of a viscoelastic medium	US13497648	HISKY MEDICAL
Method and device for obtaining motion information	US16689022	HISKY MEDICAL
Methods and equipment for detecting the viscoelastic parameters of the viscoelastic media	US16012702	HISKY MEDICAL
Elastic detection methods and equipment	US15655844	HISKY MEDICAL
Ultrasonic devices and devices that produce mechanical vibration	US16120180	HISKY MEDICAL
Use control methods, systems and medical testing equipment	US15652208	HISKY MEDICAL
Organizational morphology and elasticity information processing methods and elasticity detection equipment	US15497110	HISKY MEDICAL
Data analysis and processing method of elasticity detection equipment and elasticity detection equipment	US15660900	HISKY MEDICAL
A method and system of liver boundary	US16417529	HISKY MEDICAL
A method and system of liver boundary	US15487032	HISKY MEDICAL
Select the method and device of the detection area and the elastic detection system	US15478021	HISKY MEDICAL
Methods and device for measuring medium viscoelasticity	107121596	HISKY MEDICAL

The ultrasound probe and the ultrasound detection equipment with the ultrasound probe	EP16899140.4	HISKY MEDICAL
Methods and equipment for detecting the viscoelastic parameters of the viscoelastic media	EP16877471.9	HISKY MEDICAL
Ultrasonic devices and devices that produce mechanical vibration	EP17836306.5	HISKY MEDICAL
Organizational morphology and elasticity information processing methods and elasticity detection equipment	EP15889607.6	HISKY MEDICAL
Data analysis and processing method of elasticity detection equipment and elasticity detection equipment	EP15881700.7	HISKY MEDICAL
The ultrasound probe and the ultrasound detection equipment with the ultrasound probe	EGPCT1650/2018	HISKY MEDICAL
Elastic detection methods and equipment	EGPCT693/2018	HISKY MEDICAL
Ultrasonic devices and devices that produce mechanical vibration	EGPCT125/2019	HISKY MEDICAL
Use control methods, systems and medical testing equipment	EGPCT1634/2017	HISKY MEDICAL
Data analysis and processing method of elasticity detection equipment and elasticity detection equipment	EGPCT1343/2017	HISKY MEDICAL
An elastic detection probe	EGPCT387/2017	HISKY MEDICAL
A method and system of liver boundary	EGPCT638/2017	HISKY MEDICAL
Select the method and device of the detection area and the elastic detection system	EGPCT664/2017	HISKY MEDICAL
Fat thickness measuring instrument	202130333556.3	HISKY MEDICAL
diasonograph	202030442007.5	HISKY MEDICAL
Shear-wave tissue quantitative ultrasound diagnostic instrument	202030398047.4	HISKY MEDICAL
Shear-wave tissue quantitative ultrasound diagnostic instrument	202030399233.X	HISKY MEDICAL
Ultrasound coupled parts	202030373296.8	HISKY MEDICAL
Ultrasound coupled parts	202030373284.5	HISKY MEDICAL
Ultrasound coupled parts	202030373798.0	HISKY MEDICAL
Ultrasound coupled parts	202030373799.5	HISKY MEDICAL
Microscope adjustment device, vibration lens equipment and optical imaging equipment	202221682026.5	HISKY MEDICAL

European Patent Office Approval


Hisky Global Patents list (Granted)

Title (Translated, only for reference)	Application no.	Applicant
The ultrasound probe and the ultrasound detection equipment with the ultrasound probe	EP16899140.4	HISKY MEDICAL
Methods and equipment for detecting the viscoelastic parameters of the viscoelastic media	EP16877471.9	HISKY MEDICAL
Ultrasonic devices and devices that produce mechanical vibration	EP17836306.5	HISKY MEDICAL
Organizational morphology and elasticity information processing methods and elasticity detection equipment	EP15889607.6	HISKY MEDICAL
Data analysis and processing method of elasticity detection equipment and elasticity detection equipment	EP15881700	HISKY MEDICAL



Europäisches Patentamt
European Patent Office
Office européen des brevets

European Patent Office
80299 MUNICH
GERMANY
Tel: +49 89 2399 0
Fax: +49 89 2399 4465



Grey, Ian Michael
Venner Shipley LLP
200 Aldersgate
London EC1A 4HD
ROYAUME-UNI

Formalities Officer
Name: Mohr Ferro V., M
Tel: +49 89 2399 - 7905
or call
+31 (0)70 340 45 00

7 - 1126

Ref.
IMG/118871EP1

Date
20.06.2023

Medical Technologies Co., Ltd.



European Patent Register

Deutsch English Français
Contact

← About European Patent Register Other EPO online services → Register Alert (email alerts)

Smart search Advanced search Help

About this file: EP3656310

Refine search ST36 Show history Espacenet Submit observations Report error Print

EP3656310 - METHOD AND DEVICE FOR QUANTIFYING MEDIUM VISCOELASTICITY [Right-click to bookmark this link]

Legal status

Federated register

Event history

Citations

Patent family

All documents

Status

Grant of patent is intended
Status updated on 30.11.2022
Database last updated on 31.01.2023


Most recent event

31.01.2023	New entry: Receipt of the translation of the claim(s)
31.01.2023	New entry: Payment of fee for grant
31.01.2023	New entry: Payment of fee for publishing/printing


Applicant(s)

For all designated states
Wuxi Hisky Medical Technologies Co., Ltd.
B401
530 Plaza, University Science Park
Tajhu International Science & Technology Park
Xinwu District, Wuxi
Jiangsu 214000 / CN
[2020/22]

Global Registration



Global Installation



2500+
Global
Installation



HISKY products so far installed in more than **50** countries and regions worldwide.

Awards





Huang Jiasi Biomedical Engineering (BME) Award.



Chinese Medical Science and Technology Award




Chinese patent award of excellence



Splendid moment



Oct.2021 HISKY was praised by the Premier Li Keqiang



Vice Premier of the state Council



State Councilor



Vice chairman of the NPC standing committee



Vice chairman of the NPC standing committee


iLivTouch

Non-Invasive Solution for Liver Diagnosis based on **Transient Elastography (TE)**




Transient Elastography

A Technology for Tissue Stiffness Measurement




TE is widely recommended in the clinical guidelines of leading organizations worldwide.

Clinical Advantages



[Liver Stiffness Measurement, LSM]



[Ultrasound Attenuation Parameter, UAP]

Non-Invasive

Quantitative

Accurate

Rapid

TE can be considered the non-invasive standard for the measurement of LS. (A1)

EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis, Journal of Hepatology 2015 vol. 63 j 237–264



Examination Report



Name of Hospital Examination Report

Name: ** Gender: M Age/D.O.B.: 28
 Height: 162cm Weight: 75kg BMI: 28.6

ID (Exam No.): Referring Clinic:
 Physician: Note:




Measurements
 ▶ Success Rate **100%**
 ▶ Valid/Total **10/10**

LSM: 9.1 kPa
Stiffness

Stiffness
 Median **9.1 kPa**
 IQR/Median 6%

Liver Stiffness Measurement




*It is suggested to combine with serological test results for judgment.

UAP: 262 dB/m
Steatosis

UAP
 Median **262 dB/m**
 IQR/Median 10%

Ultrasound Attenuation Parameter



For reference only. Please consult your physician for further diagnosis.

Parameter	Value	Description	Recommendations
	< 7.4 kPa	Normal range	
LSM (CHB, Elevated ALT, but <5 x ULN)	7.4 kPa - 12.4 kPa	May have significant liver fibrosis	Further clinical examinations are recommended. Or follow your physician's advice, have TE examination every 3-6 months for monitoring and assessing the dynamic changes. Change unhealthy lifestyles, e.g. smoking, heavy drinking, stay up late, unhealthy or irregular diet, lack of exercises, etc.
	≥ 12.4 kPa	May have advanced liver fibrosis, if acute inflammation excluded, may have the trend of liver cirrhosis	Further clinical examinations are recommended to identify the etiology, e.g. serological examination, imaging examination. In clinical practice, the following causes may lead to high LSM: virus hepatitis, fatty liver, alcoholic liver disease, drug-induced liver injury, autoimmune liver disease, biliary tract disease, etc.
	< 244 dB/m	Normal range	
UAP	244 dB/m - 269 dB/m	May have mild fatty liver	A balanced diet with low fat and moderate carbohydrates, avoiding being sedentary, and maintaining moderate aerobic exercise are recommended. 3-6 months for monitoring and assessing the prognosis.
	≥ 269 dB/m	May have moderate to severe fatty liver	Lifestyle modifications, regular monitoring and evaluation are recommended. For those with abnormal LSM reading, it is recommended referral to a specialized center for further screening and evaluation, and follow physician's advice.

ⓘ **Confounders for reliable LSM: liver ascites, narrow intercostal space, liver inflammation (elevation of ALT, elevation of bilirubin, etc.), cholestasis, hepatic congestion, alcohol consumption, etc.**

Time:


Operator:

※Probe must be calibrated according to the manufacturer's recommendations.




Clinical Application



Application of TE Across Chronic Liver Diseases Spectrum: **Screening, Follow-Up, Prognosis**



Target Clinical Departments



- Viral Hepatitis (B, C)
- Non-alcoholic fatty liver disease (NAFLD)
- Alcoholic liver disease (ALD)
- Drug-induced liver injury (DILI) & Toxic liver injury
- Metabolic diseases-induced liver injury
- Autoimmune liver disease
- Primary biliary cirrhosis
- Biliary tract disease
- Prediction of liver-related events
- General population



Academic exchanges between Chinese and Russian experts



Years of Technology Accumulation

Starting in 2014, after 8 years of research, the self-developed CellTouch confocal laser micro-endoscope obtained the medical device registration certificate.



CLE — CellTouch

Real-time & non-invasive optical biopsy system, creating a new method of early cancer screening

High Image Quality




Image of Hisky





Image of other manufacture


Fast Operation and imaging



Real-time Dual Image Display
User-friendly Operation



Wide application of Product



Презентация 10

Juventus

Juventas Is The Pioneer and Leader in Cell Therapy in China



From 0 to 1, Pave the Way for Commercialization



Focus on Cell Therapy, Lead a Healthy Future

1 Commercialized Product: Ina-cel

- Approved indication: Adult r/r B-ALL, Ina-cel is the only one CAR-T product for this indication that get approved in China
- Full coverage of indications: B-NHL, Pediatric B-ALL, autoimmune diseases
- Global patent layout and global business development

10+ Pipelines

- Hematologic malignancies
- Solid tumors
- Autoimmune diseases
- Regeneration medicine

4 Innovative Platforms

- Autologous CAR
- Next CAR
- Universal CAR
- iPSC

1 Manufacturing Facility

GMP manufacturing facility in Tianjin, China

~120 Commercialization Employees

In charge of the business development and commercial production

~200 R&D Employees

In charge of R&D and production of each pipeline


6 INDs

5 in China
1 in USA

75 Patent Applications

37 Granted Patents

Key Milestones Achieved



Ina-cel Is China's First Original CAR-T Product in Leukemia

1st in China and 2nd in the world


- In November, 2023, Ina-cel was approval by NMPA for adult r/r B-ALL¹, which is **1st** in China and **2nd** in the world

2 Differentiated structure for BIC potential in efficacy and safety

- Unique CD19scFv (HI19a)** with high specificity and binding affinity², second - generation CD19-CAR structure with **national invention patent**
 - 4-1BB co-stimulatory domain**, reduces the severity of CRS³ and ICANS⁴ while maintaining long-term anti-tumor effects⁵
- High and durable response**, ORR⁶ 82.1%, CRR⁷ 66.7%, MRD-⁸ 100%, a median follow-up of 8 months, the median DOR⁹/ RFS ¹⁰/ OS¹¹ were not reached

3 Diversified Indication expansion

- r/r NHL¹²: expecting NDA submission in 2024 and NDA approval in 2025
- pediatric r/r B-ALL: expecting NDA submission in 2025 Q1 and NDA approval in 2026
 - autoimmune diseases : IIT study undergoing, expecting IND study in 2024




5 Multiple regulatory recognitions, global IP rights

NMPA "breakthrough therapy designation"

FDA "Orphan Drug" Designation

NMPA "Priority Review Channel" Drugs



4 World-leading CMC process

- Vein to vein time: 19-24 days
- 100%** success rate in clinical trial for ALL patients
- Four plasmid packaging system and serum-free culture system
- Enclosed and automated manufacturing process
- Enriched with high proportion of central memory T cells

Note 1: Relapsed or refractory B-cell acute lymphoblastic leukemia; Note 2: Gu R, et al. J Hematol Oncol. 2020 Sep 7;13(1):122; Note 3: Cytokine release syndrome, a toxic adverse event; Note 4: Immune effector cell-associated neurotoxicity syndrome, a CAR-T cell therapy-related nervous system toxicity; Note 5: ASTCT Slide; Note 6 : Objective response rate; Note 7: Complete response rate; Note 8: Minimal residual disease detection; Note 9: Duration of response; Note 10: Relapse-free survival time; Note 11: Overall survival; Note 12: Relapsed or refractory B-cell non-Hodgkin's lymphoma

Презентация 11

RealMind

RealMind Biotech

— For Better Diagnosis!

RealMind Biotech
Marketing dept.
June 2024



www.realmindbio.com



RealMind: For Better Diagnosis!

In RealMind Biotech, we dedicate to offering the best In-vitro diagnosis products to hospitals & clinical labs, focusing on children & the elderly healthcare.



Started up
June 2015



> 100 million financing
by Sequoia Capital and others




National
High-Tech Enterprise



Partnership with
Roche Diagnosis and GenSci

Cooperation with the research team of **Dr. Gu**, a member of the **Chinese Academy of Sciences**, on the application of high-performance magnetic beads in IVD industry



University-Industry Cooperation & Clinical Research Projects



Published English articles of CLIA key projects on *Nature communication*, *Analytical chemistry*, etc.

Research data & review article published on *Chinese Medical Journal*



Compact Chemiluminescence Immunoassay (CLIA) System

- ✓ 77 NMPA registered reagents
- ✓ 129 CE registered reagents



ACL2800 series

Fully-auto CLIA analyzer

- Big-capacity bench-top CLIA analyzer
- Stable & Efficient



MCL60

Fully-auto CLIA analyzer

- Whole blood mini CLIA analyzer
- Fast, Convenient, Accurate, Efficient



A6i

Fully-auto CLIA analyzer

- Next-Gen Whole blood mini CLIA analyzer
- Sample tube auto recognition & auto de-/re-cap
- Open to lab automation track connection



**Whole Blood CLIA Emergency Tests,
Fast Management of
Acute & Severe Patients**

- **Cardiac**
- **Inflammation**
- **Cytokines**
- **Thrombotic Disease**
- **Cerebral Injury**



**Finger Blood Children Tests
& Full cycle Pregnancy Monitoring**

- **Child Growth & Development**
- **Fertility**
- **Birth Defect Screening**
- **Preeclampsia**
- **Anemia**



**Elderly & Chronic Disease
& Other Healthcare**

- **Gastric function**
- **Glycometabolism**
- **Thyroid**
- **Tumor**
- **Alzheimer's Disease**



**Whole blood
fast test**

Faster management for
acute patients



**Finger blood
easy test**

Microsample finger blood
test for children




**DBS
sample**

Easy accessibility & sample
transportation

Emergency & ICU product

➤ Partnership with Roche Diagnostics (China)

Roche Diagnostics (China) will be the exclusive agent of RealMind MCL60 CLIA analyzer, along with a list of selected CLIA reagents, for clinical departments in mainland China.



Children Healthcare product

➤ Partnership with GenSci

RealMind Biotech and GeneScience Pharmaceutical (“GenSci”) will work together to create the Child Growth & Development screening - rhGH treatment closed-loop solution.




Brand building & events



Education with KOLs



Active participation in nationwide conventions in China



2023 MEDLAB Middle East



2023 MEDLAB Asia



2023 AACCC(ADLM)



2024 International Workshop

COVID-19

During the COVID-19 pandemic in 2020, RealMind engineers had personally went to HuoShenShan hospital in Wuhan to help fight the pandemic.



the Elderly Healthcare

RealMind had joined the Dementia Early Screening Program by Jiangsu Provincial Health Commission in 2023 to fight the growing cases of dementia in China.



Children Healthcare

RealMind had actively organized and joined in Children Healthy Growth charity clinics in different cities in China.





**THANK
YOU**



For Better Diagnosis!

NANJING REALMIND BIOTECH CO.,LTD

Презентация 12


Stedical



Bringing Disruptive Innovation to Healthcare

A Global Innovative Company in Tissue-Engineering and Regenerative Medicine

2024



Stedical Scientific: a tissue engineering and regenerative medicine company with the world's exclusive original biosynthetic membrane material technology



Stedical Scientific Inc. is a global tissue engineering and regenerative medicine company. It has a proprietary technology platform for biosynthetic membrane repair. The company has R&D centers and manufacturing facilities in San Diego, California, USA and Shanghai China. In 2021, it won the first place among the "Global TOP 10 Wound Management Solution Providers".

Stedical's Chief Scientific Officer is the inventor and founder of the world's first biosynthetic membrane repair material. The technology platform can be applied in the fields of wound repair, surgery, orthopedic trauma, neurology, cardiovascular, and other indications. Stedical's product, PermeaDerm Biosynthetic Wound Matrix, is FDA cleared and reimbursed as Skin Substitute High Cost Group product in the US clinical market.

The company's core values include building the most innovative and safe products, providing the highest customer service while creating a culture of integrity and appreciation for its employees. Stedical's products accelerate the clinical application of innovative regenerative medicine technologies around the world, while greatly improving patient outcomes and the clinician experience. The company's driving spirit and daily efforts are committed to discovering the potential for hidden therapeutic solutions and matching these innovations to unmet clinical needs.


Stedical Scientific
"state-of-the-art medical + Scientific"



Stedical_Global Development

Steadily advancing global business layout, continuously growing business value, and benefiting patients worldwide

10 countries:
China, United States, Saudi Arabia, UAE, Oman, Bahrain, Egypt, Singapore, Indonesia, Malaysia



■ Regional coverage of approvals ■ Registered regions ● Clinical trials completed
○ Clinical trial in progress 🚩 Commercial (cooperative) team



PermeaDerm[®]
Biosynthetic Wound
Matrix

FDA 510(k) Cleared Device reimbursed as Skin Substitute High Cost Group

A **Biosynthetic Matrix (BSM)** Technology

Bilaminate skin substitute

- Silicone membrane
- 3D micro-support system + bio-coating

Epidermal Analogue

Dual channel silicone membrane to maximize **oxygenation**: enabling oxygen, carbon dioxide and exudate to diffuse to/from the wound as needed.

Slits enhance fluid management.





Dermal Analogue

3D micro scaffold

Permits cell migration, proliferation and ingrowth.

Bioactive coating

ECM reconstruction to facilitate adherence and proliferation of cytokines and growth factors.



Acute Wound



Female, 19m old - 13% TBSA, **scald burns** to bilateral hands/fingers from hot bathtub



Chronic Wound

C



DFU - 1yr 3 months duration



PermeaDerm® C 1st application
on Aug 30, 2017



After 1 week



PermeaDerm® C 2nd
application
on Sep 6, 2017



After 1 week




PermeaDerm® C 3rd
application
on Sep 13, 2017



Healed
Sep 20, 2017

Indications

Product Configuration



Partial thickness burn wounds,
Donor sites
Coverage of meshed autograft

Chronic Wounds

- Pressure sores
- Venous ulcers
- Diabetic ulcers
- Chronic vascular ulcers

Surgical wounds

- Donor sites/grafts
- Post-Moh's
- Post-laser surgery
- Podiatric
- Wound dehiscence,

Acute wounds

- Abrasions
- Lacerations
- 2nd degree burns
- Skin tears
- Draining wounds

Debrided partial thickness hand burns



Stedical
SCIENTIFIC

Thank you

Презентация 13

TeddyLab

Teddy Clinical Research Laboratory

Introduction

The One-stop Central Lab Service for Clinical Trials



观合医药

Teddy Clinical Research Laboratory

Clinical trials is fundamental for new drug development

Central laboratories provide reliable data for clinical trials

Teddylab offers you with full service solution for central laboratories



Teddylab: Facts in a nutshell



12

Years of Clinical Samples Testing Experience

1100+

Studies Supported
(Phase I-IV, 25 MRCT, 50 Vaccines)

2000+

Test Items

35

NMPA Inspections
(Covid-19: 6 vaccines and 4 small molecules treatment approval)

750,000

+

Clinical Samples Tested

12 years excellence of central laboratories together with clients

Strategic clients showcase





**Teddylab is committed to connect China and Russia
for innovative drug development**




Thank You !

Powering the Healthcare Development

总部：上海市杨浦区翔殷路128号12号楼3楼
邮编：200433
电话：+86 21 6123 0400
传真：+86 21 0695 2736

Copyright © 2020 Teddy Clinical Research Laboratory. All rights reserved.



Презентация 14

Thoth

DRIVE INTEGRATED CARDIOVASCULAR CARE SOLUTIONS WITHIN TIGHT-KNIT MEDICAL ALLIANCES

The application of wearable medical sensors and
AI technology in the cardiovascular field

ABOUT US



18[^] NMPA Certificates

70₊[^] Patents

4,000₊[^] Hospitals

4,000,000₊[^] Users




THOTH Medical, headquartered in Suzhou, China. We focus on providing accurate, efficient, comfortable and safe clinical medical services for every user and innovatively designed disposable sensors similar to "Band-Aids", integrating product and service values into the sensors to build a new medical ecosystem. Our product line covers multi-vital signs areas such as ECG monitoring, fetal heart monitoring, multi-parameter monitoring and polysomnography, which triggers the upgrade of patient experience. Our quality policy is to provide reliable and efficient clinical-grade digital medical sensor infrastructure for the healthcare ecosystem.

WHAT WE PROVIDE-COMPLETE SOLUTION




ECG, Emotion, Sleeping, Sports measurement & Real time monitoring (up to 7 days)



Fast data Analysis & Reports Generating



NEED FOR LONG-TERM ECG MONITORING



- Significantly improve the diagnosis rate of arrhythmias: arrhythmias are often intermittent and sporadic.
- Continuous tracking to assist doctors' treatment plans for patients using antiarrhythmic medications or those with pacemakers.
- Detect early signs of potential cardiovascular events (stroke, cardiac arrest), allowing for timely intervention and reducing patient risk.

*Diagnostic Utility of a Novel Leadless Arrhythmia Monitoring Device

—Mintu P. Turakhia, MD, MASA,b,* , Donald D. Hoang, BAa , Peter Zimetbaum, MDc, Jared D. Miller, MDa,b , Victor F. Froelicher, MDa,b , Uday N. Kumar, MDd , Xiangyan Xu, MSA , Felix Yang, MDa , and Paul A. Heidenreich, MD, MSA,b

The American Journal of Cardiology (www.ajconline.org)

PRODUCT MATRIX




REGAIN™ Series Single-lead Product

**LARGE SCALE USE
IN HOSPITALS**

Always-ready
Increase efficiency

No charging

7 days duration




REGAIN™ Series Multi-leads Product

**LARGE SCALE USE
IN HOSPITALS**

Simultaneously monitoring data
from three leads

No charging

7 days duration



LINKGAIN® Single-lead Product

**LONG TERM HEALTH
MANAGEMENT OF PATIENTS**

IPX7 waterproof
Lower cost for long-term use

Rechargeable

7 days duration



on the go Single-lead Product

**LOW THRESHOLD AND
QUICK DECISION FOR USERS**

IPX7 waterproof
Recommended for first-time use

Disposable

7 days duration

Consistent with traditional Hotter by over 97%

COVER 53% OF TOP 100 HOSPITALS IN CHINA

Total **4,340,518**



Top 15 Hospitals

1	首都*****安贞医院	51708
2	复旦****中山医院	30600
3	上海****中心医院	27952
4	江苏***人民医院	22584
5	河南*****人民医院	13296
6	河南*****人民医院	12960
7	河南*****团总医院	12504
8	河南****中心医院	10416
9	广西*****人民医院	10080
10	河南*****附属医院	8912
11	南京***江宁医院	8312
12	辽宁****中心医院	9288
13	辽宁****中心医院	8928
14	南京***机关医院	8712
15	江西*****人民医院	8688

■ Operation Volume

Total **5355**

Left Atrial Appendage Occlusion

Total **43181**

Permanent Pacemaker Implantation

Total **53793**

Catheter Ablation

Total **271579**

PCI

Total
4,323,155

Arrhythmia Discovered

Total
2,461,073

Frequent APB Discovered

Total
1,788,293

Frequent VPB Discovered

Total
1,228,366

ST-T Change Discovered

Total
746,569

Af/AF Discovered

Total
572,948

Long R-R Intervals($\geq 2s$)
Discovered

INNOVATIVE COOPERATION MODEL



- Provide technical services
- Connect the links between upper and lower level hospitals
- Improve work efficiency in each link



- As quality control centers
- Building academic and scientific research highlands



TERTIARY HOSPITALS


- Play a role in screening, diagnosis, and follow-up
- Transport truly needed patients to central hospitals for treatment




providing big data
providing data processing services



GRASSROOTS HOSPITALS




Provide support for hospitals of all levels, and interconnect medical resources



Current Situation and Opportunities

Large patient population leads to a significant increase in hospital workload



Current Situation and Opportunities


Low professional medical level, shortage of medical resources and equipment



Current Situation and Opportunities

Untapped market, enormous potential, no need to purchase equipment, no need for professional data processing personnel

VISION



FOR THE COUNTRY



THANKS

WeChat



WhatsApp



Judy Ai +86 158 6232 7371

Judy@thothcloud.com

THOTH (Suzhou) Medical Technology Co., LTD

Презентация 15

ZHIDA Pharma



智达药业
ZHIDA Pharma

Nano Drug Delivery System Enterprise

Company Profile



- ◆ Zhejiang Zhida Pharmaceutical, founded in 2018 and located in Shaoxing Binhai New Town Medical device Science and Technology Industrial Park, is a research and development enterprise **focusing on nano drug delivery platform technology and industrialization.**
- ◆ The company has a **complete** liposome drug loading technology platform, the core product of Doxorubicin hydrochloride liposome injection for the variety of the first new registered classified generic drug application approved, 2023, it reached a sales revenue of more than **100 million RMB.** Follow-up products cover tumor, analgesia and anti-infections.

1st


Approved with the new NMPA classification standard

Milestones

- The liposome production line was completed and GMP verification was completed

- Registration and application of doxorubicin hydrochloride liposomes
- Completed the R&D of irinotecan liposomes

- Doxorubicin hydrochloride liposomes were approved
- BE testing of irinotecan liposomes was completed
- Awarded with national high-tech enterprise identification




- Zhida Pharmaceutical was registered and established
- Completed the R&D of Doxorubicin hydrochloride liposome and BE study of pharmaceutical consistency

- Completion of BE trials of Doxorubicin hydrochloride liposomes


- Accelerate the development of a technology platform for sublingual macromolecular drug delivery

Liposome technology platform


Category	Single compartment liposome		Long-acting sustained-release liposome	
	PEG Modified Long Circulating Liposomes	Flexible liposome	Multilayer liposome	Polycystic liposome
Technical characteristics	PEG modification can endow liposomes with concealed function, which can evade the phagocytosis of human RES system and passively target the release of drugs at the lesion site to exert curative effect.	Adding surfactant or permeation enhancer has good flexibility and strong permeability, and can penetrate mucous membrane tissue or skin tissue efficiently.	Multilayer chambers formed by concentric lipid bimolecules are distributed in aqueous phase or locally released in lipid bilayer.	Foam-like spherical aggregates formed by non-concentric multi-cystic lipid bimolecular vesicles are closely packed to enable local drug release
Advantage	Specific permeation through tumor vascular tissue and enrichment in tumor tissue with low toxicity and high efficiency	It can be administered locally, and the toxicity can play a therapeutic role efficiently. Patients have good compliance.	The patients who can release drugs by local administration usually have good compliance when they are given at one time for a long time.	
Product	Doxorubicin hydrochloride liposome injection (Listed) Irinotecan hydrochloride liposome injection (BE Filing)	Insulin sublingual liposome (Small-scale study)	Ropivacaine multilayer liposome (Small-scale study)	Bupivacaine polycystic liposome (Small-scale study) Ropivacaine polycystic liposome (Small-scale study)



PEG modified long-circulating liposomes



Flexible liposomes




Multilayer liposomes




Polycystic liposomes

Core product - Doxorubicin hydrochloride liposome

- ◆ Doxorubicin is an anthracycline anti-tumor drug. It plays a very important role in the treatment of cancer because of its broad anti-tumor spectrum and its effectiveness against hypoxic cells. Doxorubicin liposome is a special dosage form, which has good solubilization and potential sustained release and targeting properties, and can play a unique drug release mechanism, which is favored by developers.
- ◆ Zhida Pharmaceutical fully refers to the requirements of the product generic guidelines published by FDA to carry out research and development work, and has realized that the self-developed product has the same composition as the reference preparation, the same content of each component, the same key quality parameters, the same release under various conditions and the same blood drug concentration in animals.



原研



生产批


PK 参数	游离多柔比星		包封多柔比星	
	F(%)	90% CI	F(%)	90% CI
C_{max}	109.15	(101.78,117.05)	100	(97.16,102.92)
AUC_{0-t}	105.91	(100.07,112.08)	102.5	(97.54,107.71)
$AUC_{0-\infty}$	107.37	(102.14,112.87)	104.3	(99.95,108.84)

图1 药代动力学指标：自研产品vs参比制剂




The core product - Irinotecan liposome


- ◆ Irinotecan, a camptothecin analogue, is used in combination with 5-fluorouracil (5-FU) and leucovorin in patients with metastatic pancreatic cancer who have progressed after gemcitabine treatment.
- ◆ In the Asian subgroup of the Irinotecan liposomal clinical study NAPOLI-1, survival benefits were more pronounced in the Asian population than in the overall population, with a median OS extension of 5.2 months and a median PFS extension of 2.6 months.
- ◆ Zhida Pharmaceutical's Irinotecan liposome product has passed the clinical BE. The data stability of the detection method is good, and the results of ISR are good. Benchmarking 10 billion market.
- ◆ **FDA approved as a first-line drug for the treatment of metastatic pancreatic cancer, and the product is expected to be approved for a variety of other indications in the later stage, and the market potential will expand.**



RLD




ZD batch








Core product -- Ropivacaine liposomes

- ◆ Ropivacaine hydrochloride is a type of **long-acting amide local anesthetic**, which has the **dual effect of anesthesia and analgesia** and is widely used in various surgical applications. Compared with bupivacaine, Ropivacaine is a better-studied product with **low central nervous system and cardiac toxicity** and a stable position in the anesthesia market.
- ◆ The preparation form is freeze-dried, **the stability is better than suspension forms**, and different release behavior can be designed according to the needs of different indications. It can be terminal debacterialized and filtered, and the aseptic risk is controllable.
- ◆ Compared with free drugs, ropivacaine liposomes of Zhida Pharmaceutical have obvious sustained release effect in vivo and in vitro. The sustained release behavior can be adjusted according to prescription at the same dose, and the longest analgesic time is much longer than that of bupivacaine liposome suspension on the market. It is expected to be used as an exclusive product to benchmark the 16 billion RMB post-operative analgesia market.



Future planning -- progress of the research project

Therapeutic field	Developing products	Indications	R&D	Clinical	NDA	Commercial
Anti-tumor	Doxorubicin hydrochloride liposome injection	Breast/ovarian cancer and many other tumors				2023
	Irinotecan liposome injection	Pancreatic cancer (lung cancer/gastric cancer/esophageal cancer and other European and American clinical stage II/III)				2025 
	Docetaxel albumin-bound for injection	Multiple solid tumors		2025		
	Epirubicin hydrochloride liposome injection	Multiple hematoma and solid tumor	2024			
	Daunorubicin cytarabine liposome for injection	Leukaemia	2024			
	Mitoxantrone liposomes	Broad-spectrum antitumor drugs widely used in clinic	2024			
Analgesia	Ropivacaine liposomes for injection	Local long-acting analgesia		Clinical 2024	2025 Sino-us double Report 	
	Bupivacaine Meloxicam slow-release gel	Based on the analgesic effects of bupivacaine, meloxicam reduces wound inflammation and relieves pain; Improves the local pH value of the wound, so that the pH value tends to normalize and allow more bupivacaine to penetrate the cell membrane, to achieve a synergistic analgesic effect.		2027		
Anti-infections	Amphotericin B liposomes for injection	Invasive fungal infection	Prepare for subsequent export cooperation, strive to obtain the US \$400 million market, but also can be sold to domestic, to meet the growing clinical demand in China. FDA ANDA by 2027.			
	Modified preparation of polymyxin B	Used to treat various infections	2024			
Metabolism	Insulin sublingual liposome preparations	Type II diabetes	2024			

Shaoxing production plant

Shaoxing factory has completed the relevant verification in accordance with GMP requirements, with a total area of about 4800 square meters.





智达药业
ZHIDA Pharma

THANK YOU